Drugs / sacubitril/valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03066804 | Aug 2017 → Oct 2019 | diastolic heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-03-31 | Novartis Pharmaceuticals | Regulatory Novartis Entresto receives positive CHMP opinion for pediatric heart failure novartis.com ↗ |
| 2017-11-12 | Novartis Pharmaceuticals | Results New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure novartis.com ↗
Entresto significantly reduced levels of NT-proBNP, a key blood marker associated with cardiovascular risk in patients with heart failure; the magnitude of the decrease was similar to that observed in the PARADIGM-HF study[1] |
| 2017-03-22 | Novartis Pharmaceuticals | Results Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure novartis.com ↗
RELAX-AHF-2 did not meet its primary endpoints of reduction in cardiovascular death through Day 180 or reduced worsening heart failure through Day five when added to standard therapy in patients with AHF. |
| 2016-06-22 | Novartis Pharmaceuticals | Results Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology novartis.com ↗ |
| 2016-04-02 | Novartis Pharmaceuticals | Results New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless... novartis.com ↗
In a second analysis, patients taking Entresto had about a 20% reduction in CV death or heart failure hospitalization compared to those taking enalapril, regardless of background therapy[1],[2] |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sacubitril/valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03066804 ↗ |
| Route | Oral | “to be taken orally” NCT03066804 ↗ |